Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 Earnings Call Transcript February 26, 2026Kymera Therapeutics, Inc. misses on earnings expectations.
Kymera Therapeutics Inc. (KYMR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 8,657,242 | $673,620,000 | +31% | 3.94% |
| 2. | VenBio Select Advisor Kurt Von Emster | 7,474,747 | $581,610,064 | +18% | 5.72% |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,502,710 | $428,165,865 | 14.41% | |
| 4. | Siren L.L.C. Raymond Debbane | 3,286,830 | $255,748,242 | -5% | 7.63% |
| 5. | Driehaus Capital Richard Driehaus | 1,069,238 | $83,197,409 | +14% | 0.57% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.00 | 1,838,621 | $158,121,406.00 | 7,955,916 | 2025-12-11 | Filing | |
| $86.00 | 167,192 | $14,378,512.00 | 701,326 | 2025-12-11 | Filing | |
| $44.00 | 58,780 | $2,586,320.00 | 353,412 | 2025-06-30 | Filing | |
| $44.00 | 115,783 | $5,094,452.00 | 2,219,858 | 2025-06-30 | Filing | |
| $44.00 | 142,604 | $6,274,576.00 | 2,798,795 | 2025-06-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $93.49 | 8 | $747.92 | 666,195 | 2026-02-25 | Filing | |
| $92.81 | 1,501 | $139,307.81 | 666,203 | 2026-02-25 | Filing | |
| $91.76 | 3,293 | $302,165.68 | 667,704 | 2026-02-25 | Filing | |
| $90.39 | 5,434 | $491,179.26 | 670,997 | 2026-02-25 | Filing | |
| $89.78 | 19,764 | $1,774,411.92 | 676,431 | 2026-02-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,928,574 | $694,732,353 | 0.04% | |
| 2. | 6,267,644 | $487,685,380 | 0.01% | |
| 3. | 5,004,095 | $389,368,651 | 0.01% | |
| 4. | 4,659,874 | $362,584,796 | 41.91% | |
| 5. | 4,412,933 | $343,370,317 | 0.06% |
News See All
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the 14 best booming stocks to buy right now.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress
Kymera Therapeutics soared to a new all-time high on Monday after rallying for four consecutive days, as investor sentiment was boosted by the stellar results of its clinical trial to test the efficacy...
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2025 Earnings Call Transcript November 4, 2025Kymera Therapeutics, Inc. misses on earnings expectations.
Why Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories?
Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the best high-beta stocks to buy now.
10 Best High Beta Stocks to Buy Now
High-beta stocks often find themselves at the center of market rallies and sell-offs, amplifying gains during bullish stretches but carrying added risk when volatility returns.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Call Transcript
Operator: Good day, everyone. My name is Olivia, and I will be your conference operator today. At this time, I would like to welcome you to the Kymera Therapeutics Second Quarter 2025 Results Call.
Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds
As per the US Bank, the healthcare in the US exhibits a large and intricate ecosystem, which is characterized by size, complexity, and influence on the broader national economy.